AstraZeneca v. Sandoz: Olaparib PARP Inhibitor Patent Dispute Consolidated
AstraZeneca, MSD International, Kudos Pharmaceuticals, the University of Sheffield, and AstraZeneca UK jointly asserted four patents against Sandoz’s ANDA for generic olaparib tablets in New Jersey. Filed in February 2024 and resolved in 119 days, the case was consolidated with the earlier-filed action 3:23-796 for all pretrial purposes.
Filing to Case Consolidated in 119 days
119 days — consolidation resolved this filing faster than typical ANDA patent trials
Cases merged: what consolidation into 3:23-796 means for both parties
Consolidation unifies related ANDA actions into one docket
Under Fed. R. Civ. P. 42(a), courts may consolidate actions sharing common questions of law or fact. Here, cases 3:23-796 and 3:24-641 were stipulated by the parties and ordered consolidated for all pretrial purposes. This means discovery, claim construction, and any pretrial motions will proceed once, under lead docket 3:23-796, avoiding duplicative litigation across two separately filed ANDA infringement suits.
Rule 42(a) consolidationPlaintiffs streamline a multi-patent, multi-filing olaparib campaign
Consolidation typically benefits plaintiffs asserting the same patents across staggered ANDA filings. By merging into a single pretrial track, AstraZeneca and co-plaintiffs avoid inconsistent rulings and can present a unified claim construction position across all four olaparib patents. The 30-month stay of FDA approval — triggered by timely Hatch-Waxman filing — continues to run under the consolidated action.
Unified patent enforcementSandoz faces consolidated multi-patent challenge on single schedule
For Sandoz, consolidation concentrates the litigation risk: invalidity and non-infringement defenses for all four patents will be litigated on a single timeline. While this reduces duplicative motion practice, it also limits Sandoz’s ability to obtain an early ruling on any one patent in isolation. The outcome of the lead docket 3:23-796 will govern the path to final FDA approval for the generic olaparib tablets.
Single-track ANDA defenseGeneric olaparib entry timeline tied to consolidated trial outcome
Olaparib (Lynparza) is a high-value oncology asset in the PARP inhibitor class. Consolidation suggests the dispute will be substantively litigated rather than quickly resolved, consistent with the complexity of four overlapping patents held across a multi-party plaintiff group. Market entry for Sandoz’s generic — and for any other ANDA filers watching this lead case — now depends on the outcome of 3:23-796.
PARP inhibitor market entry riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AstraZeneca AB | Individual | Search in Eureka ↗ |
| Co-Plaintiff | MSD International Business, GmbH | Company | Search in Eureka ↗ |
| Co-Plaintiff | Kudos Pharmaceuticals Limited | Individual | Search in Eureka ↗ |
| Co-Plaintiff | The University Of Sheffield | Individual | Search in Eureka ↗ |
| Co-Plaintiff | AstraZeneca UK Limited | Individual | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing AstraZeneca ABSearch in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consolidation order is a procedural — not merits — disposition. Neither infringement nor validity was adjudicated in this filing. The parties’ joint stipulation suggests cooperative case management rather than adversarial procedural maneuvering, which is common in Hatch-Waxman matters involving parallel ANDA filings. The substantive dispute over all four olaparib patents now proceeds exclusively under lead docket 3:23-796, and this case number carries no independent legal weight going forward.
US8859562B2 and three co-asserted patents — olaparib PARP inhibitor formulations
The four patents in suit — US8859562B2, US7449464B2, US11633396B2, and US8475842B2 — collectively cover the chemical entity olaparib and its pharmaceutical formulations as used in the commercial product Lynparza. Olaparib is a first-in-class PARP inhibitor approved for BRCA-mutated ovarian, breast, and prostate cancers. The portfolio spans application dates ranging from the mid-2000s to the early 2020s, suggesting compound, formulation, and lifecycle extension claims within a layered IP structure jointly held by AstraZeneca, MSD, Kudos Pharmaceuticals, and the University of Sheffield.
The commercial significance of this portfolio is substantial: Lynparza generated multi-billion dollar annual revenues globally prior to patent expiry risk. The inclusion of US11633396B2 — a relatively recent patent with application number 17/821833 — suggests AstraZeneca has pursued lifecycle management to extend exclusivity beyond earlier compound patents. For generic manufacturers and biosimilar strategists, the multi-owner structure means FTO clearance requires analyzing ownership, license chains, and claim scope across all four patents independently before any ANDA or 505(b)(2) strategy is viable.
Should your team run an FTO against these four olaparib patents?
Any company developing or commercializing olaparib tablets — or structurally related PARP inhibitors — in the US market should treat this four-patent portfolio as an active FTO priority. The multi-owner structure (AstraZeneca, MSD International, Kudos Pharmaceuticals, University of Sheffield) means that even a successful challenge to one patent owner’s claims may leave other enforceable claims intact. Product teams working on solid oral dosage forms containing olaparib at 100 mg or 150 mg strengths face the highest direct exposure.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope across all four patent numbers simultaneously, identify file history estoppel risks, and flag continuation or divisional applications that may not yet have been asserted. Eureka’s patent landscape tools can also surface other PARP inhibitor patents in the same family, helping teams model the full exclusivity perimeter before investing in formulation development or ANDA preparation.
Run a freedom-to-operate analysis on US8859562B2 to assess your product’s exposure
Run FTO in Eureka →Related PARP inhibitor and olaparib ANDA patent cases in NJ District Court
Explore related Hatch-Waxman ANDA infringement actions involving olaparib and PARP inhibitor patents litigated in New Jersey District Court.
What this case signals for the PARP inhibitor and oncology generics IP landscape
Multi-plaintiff, multi-patent ANDA consolidations in NJ are a key indicator of how originator pharma defends blockbuster oncology franchises.
Staggered ANDA filings often trigger staggered suits — expect consolidation
AstraZeneca filed a separate infringement action for each ANDA submission window. NJ District Court’s willingness to consolidate for pretrial purposes is a consistent pattern in Hatch-Waxman litigation. Companies monitoring generic entry timelines should track lead docket 3:23-796 rather than this closed filing.
Four-patent portfolio signals layered Hatch-Waxman exclusivity strategy
Asserting US8859562, US7449464, US11633396, and US8475842 simultaneously suggests AstraZeneca has structured overlapping patent coverage across compound, formulation, and method-of-use claims. Generic challengers face a higher burden to design around the full portfolio rather than a single claim.
AB v Sandoz — key questions answered
Consolidation means case 3:24-cv-00641 is merged with lead docket 3:23-796 for all pretrial purposes. No separate merits rulings will issue in the 641 docket. All discovery, claim construction, and pretrial motions will proceed under 3:23-796, and any judgment there will govern the olaparib patent dispute with Sandoz.
AstraZeneca and co-plaintiffs asserted four patents: US8859562B2, US7449464B2, US11633396B2, and US8475842B2. These patents collectively cover olaparib compound, formulation, and related pharmaceutical compositions. The product at issue is Sandoz’s ANDA for generic olaparib tablets at 100 mg and 150 mg strengths.
The University of Sheffield is listed as a co-plaintiff, which typically indicates it holds ownership or co-ownership rights in one or more of the asserted patents — likely stemming from foundational academic research into PARP inhibition that predates AstraZeneca’s commercial development of olaparib. Co-plaintiff standing requires all rights holders to join infringement actions under US patent law.
No merits ruling has issued in case 3:24-cv-00641. The case closed solely on procedural consolidation grounds. Substantive infringement and validity determinations remain pending in the lead consolidated action 3:23-796, which should be monitored for Markman and trial developments.
Olaparib (Lynparza) is a high-revenue PARP inhibitor used in BRCA-mutated oncology indications. Generic entry by Sandoz or others is gated by the outcome of the consolidated NJ litigation. The four-patent portfolio, multi-owner structure, and inclusion of a recently issued patent (US11633396B2) suggest AstraZeneca has pursued a layered exclusivity strategy that could delay generic competition beyond the earliest compound patent expiry.
PatSnap Eureka searches patents and litigation data to answer instantly.